Efficacy Data from the VISION Trial of Lu 177 Vipivotide Tetraxetan

Five-year follow-up from the IMpower010 trial shows atezolizumab improves overall survival vs BSC in resected stage IB-IIIA NSCLC.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

A post-hoc analysis showed suspending enzalutamide does not impact quality of life in patients with nonmetastatic hormone-sensitive prostate cancer in the phase 3 EMBARK trial.

Apalutamide plus androgen deprivation therapy does not appear to negatively impact quality of life in patients with recurrent prostate cancer, while still improving progression-free survival.